appearing for an infected person. We simulated the scenario for lower drug efficacy by lowering the amount of infectiousness reduction from 60 to 30 per cent, and susceptibility reduction from 30 to 15 per cent for infected and uninfected individuals, respectively. In addition, there is also a reduction of symptomatic probability to 45 per cent.